The LDL-c challenge in high cardiovascular risk - Integrating innovative therapies in clinical management

Oral cholesterol-lowering therapies: The basis of prevention 

Oral cholesterollowering therapies The basis of prevention

Subtitles available:  English, German, French & more

Media formats available:
  • Overview

    Achieving LDL-c targets is a very important goal in patients at risk of cardiovascular disease. Unfortunately, the majority of high- and very high-risk patients do not achieve guideline recommended LDL-c goals. In this series, four experts discuss the need and challenges to reach LDL-c targets and talk about various LDL-c lowering therapies.

    This course consists of 4 episodes. Watch all episodes, answer pre- and post-test questions, and start earning CME credits.

  • Program Highlights

    This educational program consists of four presentations on LDL-c-lowering therapies

    The evolving need and challenges to reach LDL-c targets in high-risk patients - Kausik Ray, MD - London, UK

    • According to the latest registries, the majority of high- and very high-risk patients do not achieve the 2019 ESC/EAS recommended LDL-c goals. Kausik Ray discusses how LDL-c goal attainment can be improved.

    Oral cholesterol-lowering therapies: The basis of prevention - Lale Tokgözoğlu, MD - Ankara, Turkey

    • "Oral cholesterol-lowering therapies are the basis of cardiovascular disease prevention", says Lale Tokgözoğlu. In this video, she talks about oral therapies.

    PCSK9i: Benefits across the spectrum of cardiovascular disease - Fabrice Martens, MD, PhD - Amsterdam, The Netherlands

    • Good risk stratification and optimal LDL-c lowering are key elements in treating patients at high CV risk. Fabrice Martens gives an overview of the effects of PCSK9i in lowering LDL-c and CV risk.

    Novel oral pathways in LDL-c lowering therapy: The new promise of CETPi - Erin Michos, MD - Baltimore, MD, USA

    • Erin Michos talks about CETPi as a novel opportunity for oral LDL-c lowering therapy. She explains the mechanism of action of CETPi and discusses past and ongoing studies with CETPi.
  • Instructions

    • Watch the four lectures and answer the pre- and post-test questions
    • Fill in the evaluation questions
    • Download CME Certificate

    For questions regarding this activity, please contact us at

  • Learning Objectives

    • Describe the current challenges to reach LDL-c targets in high-risk patients
    • Memorize the expected LDL-c reductions with oral combination therapy
    • Summarize the effects of PCSK9 monoclonal antibodies
    • Recall the effects of CETPi on the lipid profile
  • Target Audience

    This educational activity is designed for all healthcare professionals with an interest in management of patients with elevated LDL-c.

  • Accreditation and Credit Designation Statements

    This online course is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit.

    Through an agreement between EBAC and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

  • Commercial Support

    Funding for this educational program was provided by an unrestricted educational grant from Amgen, NewAmsterdam Pharma, Sanofi and Viatris.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of PACE-cme.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments


We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free